MIK665 (S-64315), derived from S63845, is a myeloid cell leukemia sequence 1 (MCL1) inhibitor. MIK665 has an IC 50 of 1.81 nM for MCL1.
性状
Solid
IC50 & Target[1][2]
Mcl-1 1.81 nM (IC50)
体外研究(In Vitro)
MIK665 (S-64315) has similar synergistic effects as S63845, when combined with ABT-199. The combination S64315 (0.156-10 μM) and ABT-199 (625 nM) has similar efficacy in reducing the cell viability of representative melanoma lines (MB2141, MB3616, MB3961, MB4667, A375, and 1205Lu cells).MIK665 is extracted from patent WO2016207225A1, compound Preparation 13, and inhibits H929 cell with an IC50 of 250 nM. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
ClinicalTrial
参考文献
[1]. Mukherjee N, et al. Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma. Cancers (Basel). 2020;12(8):2182. Published 2020 Aug 5.[2]. Zoltán SZLáVIK, et al. New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them. WO2016207225A1.